Translution Capital

Overview

Translution Capital is a Nordic corporate finance house specializing in strategic financial advisory and transaction services. The firm operates independently, providing customized solutions to clients' most challenging issues without the conflicts of interest inherent in large multi-product financial institutions. Translution Capital focuses on best-in-class execution as a trusted corporate finance advisor within mergers and acquisitions (M&A), equity capital markets (ECM), and debt capital markets (DCM), regardless of sector, size, or situation. The firm has a strong and proven reach to domestic, Nordic, and international institutional and high-net-worth investors. The firm's team combines venture capital investing experience with competencies and work experiences from small as well as large companies across various industries, spanning disciplines of scientific research, drug development, clinical practice, investment banking, and industry management. Translution Capital has been involved in several notable transactions, including acting as the sole financial advisor to Bawat Water Technologies AB in their IPO to private and institutional investors in March 2022, and advising Moscord Pte. Ltd. in securing a new funding round in February 2022. The firm has also acted as a financial advisor to the selling shareholders of I Am Drinks ApS on the trade sale of the company in January 2022. Translution Capital's leadership includes Jakob Schmidt, who has been instrumental in building the firm's rapidly expanding ECM practice. Jakob started his career in investment banking and eventually became Head of ECM at Carnegie Denmark. Most recently, he was CEO at Exruptive. Prior to that, he was SVP at Falck and CEO at Pharmexa. Jakob Schmidt sits on the board of the LINX Association, a non-profit partnership linking industry and universities around materials research. Other previous positions include Chairman of the Board of Directors in Gudme Raaschou Vision, Chairman of the Board of Directors in Curalogic, as well as Chairman of the Board of Directors in GemVax AS and Pharmexa Inc. Translution Capital's investment philosophy emphasizes a deep understanding of the industries in which they invest, a commitment to creating value through active ownership, and a focus on long-term growth. The firm's approach is characterized by a hands-on involvement in portfolio companies, leveraging their extensive network and expertise to drive strategic initiatives and operational improvements. Translution Capital's track record reflects a commitment to excellence in corporate finance advisory, with a focus on delivering tailored solutions that meet the unique needs of each client.